After successfully implementing fine-tuning in production, Nanologica’s product now meets the company’s own requirements for quality in all evaluated parameters.

The company is therefore continuing to formally approve products to be able delivery to customers progressively.
 
”After making further fine-tunings in one of the production steps, we now have a product that we are satisfied with and that we can proudly deliver to customers. Finally! This means that we now can move on with the first deliveries. We still have a lot to optimize in the process in order to gradually improve the production rate and production economy, but this is a major milestone that has now been achieved”, Nanologica’s CEO Andreas Bhagwani comments.

For further information, please contact
Johanna Johansson
Director IR, Communications and Marketing
[email protected]

About Nanologica AB (publ)
Nanologica develops, manufactures, and sells nanoporous silica particles for life science applications. A proprietary production method enables the company to create world-class products by precisely controlling the shape, size, porosity, and surface properties of silica particles. Through the two business areas, Chromatography and Drug Development, the company strives to increase the availability of cost-effective drugs and innovative treatments in healthcare, for the benefit of patients around the world. In Chromatography, the aim is to make diabetes drugs and other peptide-based drugs available to more patients by providing products that can lower the manufacturing costs for these drugs. In Drug Development, our inhalation platform is developed to give patients with severe lung diseases access to new or improved treatments. Nanologica is headquartered in Södertälje, and the company’s share (NICA) is listed for trade on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

This information is information that Nanologica AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-05-03 10:43 CEST.